February 28, 2024
Launch of PulseSight Therapeutics: advancing non-viral gene therapy for eye diseases
PulseSight Therapeutics SAS, a biotech company, launches with funding from Pureos Bioventures and ND Capital. It aims to validate its innovative delivery platform by advancing drugs for age-related macular diseases.